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Introdução: A hipertensão é o principal factor de risco para a carga global de doença e, em 
2016, foi associada a 10.4 milhões de mortes. Em Portugal, a hipertensão é o primeiro factor 
de risco associado à mortalidade, não havendo nenhum estudo que avalie o impacto da 
hipertensão ao longo do século 21. 
Objetivos: Proceder a uma revisão sistemática dos estudos de base populacional sobre 
hipertensão em Portugal, publicados entre 2000 e 2018, com meta-análise.  
Métodos: Uma estratégia de busca sistemática foi conduzida na Pubmed usando as palavras-
chave seleccionadas (Base-populacional; hipertensão; prevalência; Portugal). Utilizaram-se 
ainda referências de autores de relevo, do Instituto Nacional de Estatística, do Instituto 
Nacional de Saúde Ricardo Jorge, assim como artigos sugeridos pelos orientadores. 
Resultados: A prevalência de hipertensão no século 21 em Portugal é de 33% (95% IC: 27.6% - 
38.8%, I2: 45%), não havendo diferença significativa entre homens, 35.4% (95% IC: 24.3% - 
48.3%), e mulheres, 32.9% (95% IC: 27,1% - 38,4%). Nos estudos com exame físico a 
prevalência é de 37.1% (95% IC: 31.8% - 42.8%) enquanto nos estudos com hipertensão auto-
reportada é de 28.6% (95% IC: 23.6% - 34.3%). Verificou-se nos estudos com exame físico uma 
diminuição estatisticamente significativa entre as décadas (2000-2010 e 2011-2018) nos 
grupos etários <35 anos, de 16.3% (95% IC: 12.9% - 20.5%) para 6.3% (95% IC: 5.3% - 7.6%) e 
≥65 anos, de 80.4% (95% IC: 76.9% - 83.5%) para 73.2% (95% IC: 69.5% - 76.6%).  
Conclusão: A hipertensão é um problema com uma elevada prevalência e influencia na saúde 
dos portugueses. A prevalência da hipertensão é sub-estimada nos estudos com auto-reporte e 
verifica-se um aumento da prevalência com a idade. No entanto, mais estudos são necessários 
para concluir em relação à tendência da hipertensão no século 21, bem como medidas para 
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Background: Hypertension is the leading risk factor for the global burden disease and in 2016 
was associated with 10.4 million deaths for all causes. It is also an important risk factor for 
Cardiovascular Diseases with relevant influence in the outcomes and associated with 9.7 
million deaths by Cardiovascular Diseases in 2016. In Portugal, hypertension is the first risk 
factor for death, the fourth risk factor for early death and a determinant risk factor for 
stroke and ischemic heart diseases. 
Objectives: The aim of this thesis is: (i) to conduct a systematic review of population-based 
studies regarding hypertension prevalence in Portugal, published between 2000 and 2018, 
with meta-analyses; (ii) to compare hypertension prevalence between gender and age groups; 
(iii) to analyse hypertension prevalence trends over the last two decades. 
Methods: We performed a systematic literature search in Pubmed using selected keywords 
(population-based; hypertension; prevalence; Portugal). Also included in this review are 
references of recognized authors, publications of the Portuguese Statistics Institute and the 
Portuguese National Health Institute, and articles suggested by the advisors. The inclusion 
criteria applied to select studies to be reviewed and analyzed was: population-based studies, 
population 15 or more years-old and having been published in the 21th century.  Following this 
process, variables of interest were extracted and inserted in a Microsoft Excel database to 
allow for further statistical analysis. Meta-analysis and Meta-regression were conducted in the 
“Comprehensive Meta-analysis Software, V03 – trial version”. Assuming potential 
heterogeneity, random-effect model was used to run the analysis. Subgroup analyses were 
made in a “one-by-one” strategy to avoid collinearity. 
Results: Hypertension prevalence on 21th century in Portugal is 33% (95% CI: 27.6% - 38.8%, I2: 
45%) and did not have significant difference between men, 35.4% (95% CI: 24.3% - 48.3%), and 
women, 32.9% (95% CI: 27,1% - 38,4%). In studies with physical exam hypertension prevalence 
is 37.1% (95% CI: 31.8% - 42.8%) whereas in studies with self-reported hypertension is 28.6% 
(95% CI: 23.6% - 34.3%). Women have higher prevalence than men in studies with self-
reported hypertension while men have higher prevalence in studies with physical exam. There 
is a statistically significant decreasing among studies with physical exam between decades 
(2000-2010 e 2011-2018) in age-groups <35 years of age, from 16.3% (95% CI: 12.9% - 20.5%) to 
6.3% (95% CI: 5.3% - 7.6%) and ≥65 years of age, from 80.4% (95% CI: 76.9% - 83.5%) to 73.2% 
(95% CI: 69.5% - 76.6%). Algarve is the Portuguese region with lower prevalence in more 
studies.  
Conclusion: Hypertension has a high prevalence in Portugal. Self-report hypertension under-
estimate the hypertension prevalence and an increasing prevalence is demonstrated with 
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aging. However, further studies are necessary to identify the trend of hypertension on 21th, 
as well policies to improve evaluation, control and prevention of hypertension.   
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Background: Hypertension is the leading risk factor for the global burden disease and in 2016 
was associated with 10.4 million deaths for all causes. In Portugal, hypertension is the first 
risk factor for death and there are not studies about the trend of hypertension on 21th 
century. 
Objectives: The aim of this thesis is to conduct a systematic review of population-based 
studies regarding hypertension prevalence in Portugal, published between 2000 and 2018, 
with meta-analyses. 
Methods: A systematic search strategy was conducted in Pubmed using selected keywords 
(population-based; hypertension; prevalence; Portugal). References of known authors, 
Portuguese Statistics Institute, Portuguese Health Institute and articles suggested by the 
advisors were also included in this review.  
Results: Hypertension prevalence on 21th century in Portugal is 33% (95% CI: 27.6% - 38.8%, I2: 
45%) and did not have significant difference between men, 35.4% (95% CI: 24.3% - 48.3%), and 
women, 32.9% (95% CI: 27,1% - 38,4%). In studies with physical exam hypertension prevalence 
is 37.1% (95% CI: 31.8% - 42.8%) although in studies with self-reported hypertension is 28.6% 
(95% CI: 23.6% - 34.3%). There is a statistically significant decreasing among studies with 
physical exam between decades (2000-2010 e 2011-2018) in age-groups <35 years of age, from 
16.3% (95% CI: 12.9% - 20.5%) to 6.3% (95% CI: 5.3% - 7.6%) and ≥65 years of age, from 80.4% 
(95% CI: 76.9% - 83.5%) to 73.2% (95% CI: 69.5% - 76.6%). 
Conclusion: Hypertension has a high prevalence in Portugal. Self-report hypertension under-
estimate the hypertension prevalence and an increasing prevalence is demonstrated with 
aging. However, further studies are necessary to identify the trend of hypertension on 21th, 
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Hypertension, also known as the silent killer, is a chronic asymptomatic problem if not 
treated leads to target organ damage like the heart, brain, eye, kidney, small and big 
vessels. These changes could lead to several mortal outcomes like stroke, ischemic heart 
diseases (IHD), renal and heart failure.(1–3) 
Hypertension is the leading risk factor for the global burden disease(4) and in 2016 was 
responsible for 10.4 million deaths for all causes.(5) Is also an important risk factor for 
Cardiovascular Diseases (CVD) with relevant influence in the outcomes(6–8) and associated 
with 9.7 million deaths by CVD in 2016.(5) 
In Portugal, hypertension is the 1st risk factor for deaths in Portugal, the 4th risk factor for 
early deaths and a determinant risk factor for stroke and IHD.(9–11) Institute for Health 
Metrics and Evaluation (IHME) of University of Washington estimated that hypertension was 
involve in 19000 deaths and associated to 273000 Disability-Adjusted Life Years (DALYs).(5) 
The importance of systematic review and meta-analyses is well known among the scientific 
society. Select, order and systematize the knowledge about a health determinant or a disease 
help the general society to be better informed, improve the awareness and allows the 
stakeholders to take the properly policies.(12)  
Therefore, the present thesis makes an overview of hypertension as a risk factor and its 
impact, the potential outcomes and the Global Burden of CVD; a brief of the hypertension 
prevalence in the world is also made.  
However, the major aim is evaluate the hypertension prevalence in Portugal and to achieve 
this purposes was performed a systematic review with a resort to quantitative statistic 
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The aim of this thesis is to conduct a systematic review of population-based studies regarding 
hypertension prevalence in Portugal. Furthermore to compare hypertension prevalence 
between gender and age groups as well as to verify trends in hypertension prevalence over 
the last two decades. 
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The present section defined the concepts and provides an overview of hypertension which will 
be central to this dissertation. 
 
3.1. Definition 
Blood pressure (BP) is the force created when the blood, pumped by the heart, is pushed 
against the walls of blood vessels. The blood flow increases when the heart beats (systolic 
blood pressure - SBP) and decreases when heart relaxes (diastolic blood pressure - DBP). It is 
measured in millimetres of mercury (mmHg) by manual or electronic devices that give two 
values, being the highest SBP and the lower DBP.(1–3) 
Hypertension is the condition of persistent, non-physiologic elevation of systemic BP. The 
higher the blood pressure in the vessels harder will the heart will beat.(1–3) Clinically, for the 
majority of the scientific societies, this elevation is considered hypertension when, at rest, 
the SBP is equal or higher than 140 mmHg and/or DBP is equal or higher than 90 mmHg.(13–
19) 
 
3.2. Classification  
From an epidemiological perspective there is not an obvious level of BP that define 
appropriately hypertension.(2) Some scientific societies consider the levels of BP equal or 
below a 120/80 mmHg as optimal.(13–19) However, there is evidence demonstrating the 
association between BP and Coronary Heart Disease (CHD) for levels since 115/70 
mmHg.(20,21) 
In 1970’s the World Health Organization (WHO) defined Normal BP as the values below 140/90 
mmHg and hypertension to values equal or above to 160/95 mmHg. However, new studies 
began to demonstrate the decrease of average life expectancy with the increase of BP for 
values above 120/80 mmHg.(22) 
In summary, currently optimal BP values are considered by majority of the scientific societies 
to be those below 120/80 mmHg and hypertension for values equal or above 140 and/or 90 
mmHg.(13–19) The American Heart Association (AHA) recent changed the guidelines 
considering now hypertension for values equal or superior 130 and/or 80 mmHg.(23) 
In Portugal the guidelines6 for definition and classification of hypertension have the same 
standards of European Society of Cardiology (ESC) and European Society of Hypertension (ESH) 
2013 which are, SBP≥140 and/or DBP≥90 mmHg.(14) 
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3.3.  Etiology 
Hypertension is classified as primary, or essential, when no specific cause is identified. It 
accounts for at least 90% of all cases. It is classified as secondary when a specific cause such 
as renal failure is identified.(1–3) 
This distinction is not always easy. As an example, let us consider a person who is diagnosed 
as having renal failure and, simultaneously has hypertension. Often it is difficult to identify if 
hypertension resulted from renal failure or if a risk factor, like high salt intake, led to 
hypertension and to renal failure.(3) 
 
 
3.4.  Risk Factors 
A risk factor is any attribute, characteristic or environmental exposure of an individual that is 
associated with an increased probability of occurrence of a disease. Risk factors can be 
categorized as modifiable and non-modifiable. Modifiable risk factors are characteristics, 
exposures or lifestyle patterns that can be adjusted or changed to prevent the development 
of the disease, as diet or physical activity. Non-modifiable risk factors are attributes or 
characteristics in the individual that cannot be changed or adjusted, as age or family history, 
but many of them can be controlled and their effect reduced by making changes in 
lifestyle.(2,3,24,25)  
The main risk factors to develop hypertension could be biological, like gender(26,27), age(27–
31), race(28,32), family history(27,28) or genetic(33,34); environmental like pollution(35), 
dyslipidemia(31), BMI(27–29,36), waist circumference(26,28,31), physical inactivity(26,28) 
alcohol consumption(26,37), tobacco(37), high salt-intake(38,39), medication(29) or 
diabetes(27,31,37); and psychosocial like stress(40), education(26,29,30,36), household 
income(27) or marital status(30).  
Important to notice two things. First, primary hypertension could be the result of the 
interaction between genetic and environmental factors and second, with aging vasculature 
changes and the physiologic adaptations involve a rise in BP.(2,3) 
 
 
3.5.  Outcomes 
The outcomes of hypertension are events that occur in target damage organs, like renal or 
cardiovascular diseases. WHO, in the Global Health Risks Report (2009), referred that 51% of 
strokes and 47% of IHD are attributable to hypertension.(41) In 2016, hypertension was also 
responsible for 9.7 million deaths caused by CVD.(5) In context of this dissertation we will 
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3.5.1. Cardiovascular Diseases  
WHO defines CVD as disorders of the heart and blood vessels and include coronary heart 
disease, cerebrovascular disease, rheumatic heart disease and other conditions. Heart attacks 
and strokes represent 80% the causes of death by CVD.(42) Despite Scientific societies and 
health organizations use different disease clusters, when addressing CVD in this thesis we will 
consider the WHO cluster that includes aforementioned diseases. 
Since the beginning of 21th century, CVD was responsible for 64 million deaths. In 2015 
caused more than 17 million deaths, representing 31.3% of all deaths while in 2000 the same 
indicator was 27.7%. In 2015 CVD led to more than 400 millions of DALYs while in 2000 this 
value was 343 million. In 2015 ischemic heart disease was the first cause of DALYs while 
stroke was ranked 3rd.(5)  
Like many high-income countries during the past century, currently low- and middle-income 
countries are seeing an alarming and accelerating increase in CVD rates.(43) An example of 
this epidemiologic transition is the south-east Asia region where the number of deaths 
attributed to CVD raised from 2.6 millions in 2000 to 3.8 millions in 2015.(44)  
In Portugal CVD is decreasing. Official data show a decrease in the proportion of death 
attributed to CVD and in 2015 the Standardized-mortality rate (SMR) is below European mean. 
Therefore, SMR for stroke show a decreasing trend while SMR for ischemic heart disease 
remained stable.(45) 
Table 1 – Mortality over decades in Portugal 
  Mortality  
  HTN (n) CVD (n) CVDhtn (n) % 
2000 22234 43615 21071 48.31 
2010 18386 35654 16568 45.98 
2016 19042 37274 17136 46.47 
HTN: Hypertension; HTN (n): Number of deaths associated to HTN; CVD (n): number of deaths by 
CVD; CVDhtn (n): number of deaths by CVD withHTN associated;  
%: percentage of deaths by CVD with HTN associated.  
Source: www.healthdata.org 
Table 1 shows data from IHME of University of Washington about Mortality by CVD and the 
association of hypertension in deaths by CVD in Portugal. 
In 2017 Portuguese scientific societies (Portuguese Society of Cardiology and Portuguese 
Foundation of Cardiology) referred that in Portugal 35000 people die every year due to CVD, 
20000 had stroke as outcome and 1000 of myocardial infarction and that represents 1/3 of all 
deaths.(46) 
Comparing to European countries, in 2013 Portugal had a SMR for ischemic heart disease 
below European mean and a SMR for stroke above European mean.(47)  
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Between 1980 and 2008 the prevalence of hypertension decreased.(41) It is important to 
notice that, according Danaei et al, SBP decreased simultaneously.(48)  
Table 1 presents the results of 3 global hypertension prevalence studies. For the year 2000 
the estimated prevalence worldwide was 26.4% for adult population what represents 972 
million people with hypertension.(49) In 2010 hypertension prevalence increased worldwide 
and 1.39 billion people were classified as having  hypertension.(50)43 





Age Prevalence of HTN 
in last year 
consider 
People with 
HTN in last year 
consider 
Kearney P, 2005 1980-2000 ≥20 26.4%  972 million 








Mills et al (2011) observed an increasing rate in total hypertension prevalence and among 
both genders. They analysed the trends in high, middle and low-income countries and 
concluded that hypertension prevalence decreased in high-income countries, affecting 349 
million people, and increased in middle and low-income countries, with an 1.04 billion in 
2010. 
More recently, Zhou et al (2017), concluded that hypertension prevalence decreased in high-
income and some middle-income countries, remaining unchanged elsewhere.(51) However, 
they also concluded that hypertension prevalence decreased between 1975 (men: 29.5%; 
women: 26.1%) and 2015 (men: 24.1%; women: 20.1%). 
These studies different conclusions may have to do with sampling differences, age range and 
the period of the study. Despite these differences it is well demonstrated the heavy global 
burden of hypertension. 
An overview of data from studies in countries or regions around the world demonstrate a 
decreasing prevalence in Brazil(52), a decline in Central China but a rise in other regions 
especially in southwest(53); prevalence is higher in middle income countries compared with 
low income countries(54), in addition, urban/rural comparisons reveal that India rural regions 
are lesser hypertensive than urban area(55). Furthermore, in sub-Saharan Africa the 
prevalence is increasing(56) and in United States of America (USA) a stable prevalence around 
29% is observed in the present century.(57) 
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3.6.2.  Portugal 
In Portugal a systematic review of data between 1990 and 2005 reveals a decreasing in 
prevalence of middle-aged and older adults and a constant value in young adults.(58) 
However, when we compare the studies of Macedo et al (2005) and Polónia et al (2014) no 
differences are observed over a decade.(59,60) 
Macedo et al (2015) demonstrate an overall prevalence in Primary Healthcare Centres (PHC) 
users smaller 15%  than Polónia et al (2014) presented.(60,61) 
Recent data from a national health survey with physical exam, INSA (2016), reveals a 36% of 
prevalence.(62) 
WHO data for the year 2015, reveal that Portugal had a prevalence above the European mean 
(23.2%).(63) 
 
Table 3 - Hypertension Prevalence in Portugal 
First author’s 
article, year 
Period of Data 
Collection 
Age Prevalence of 
Hypertension  
Macedo ME, 2005 2003-2004 18-90 42.1%  
Polónia J, 2014 2011-2012 18-90 42.2% 
Macedo ME, 2015 2013 ≥18 26.9% 
INSA, 2016 2015 25-74 36.0% 




Hypertension Prevalence in Portugal: Systematic Review and Meta-analysis of Population-based Studies 
on 21th Century 
8 
 
4. Materials and Methods 
The present section follows the principles/guidelines for Strengthening the Reporting of 
Observational Studies in Epidemiology – STROBE.(64) 
The STROBE Statement was published in 2007 in several journals in order to encourage 
dissemination (STROBE checklist). It consists of a checklist and a flow diagram to improve the 
evaluation of strengths and weakness of observational studies. 
In the next sections we will address the specific objectives of this dissertation. 
4.1. Literature Review 
A systematic search was conducted in the Cochrane and Pubmed electronic article database 
using the following strategy: ((((population-based)) AND (((hypertension)) AND (prevalence)))) 
AND (Portugal). A systematic review on the prevalence of hypertension in Portugal was 
identified.(58) The author published results regarding trends in hypertension prevalence 
between 1990 and 2005.  
The aim of this systematic review is to update the aforementioned study more than a decade 
later, considering the relevant data on hypertension prevalence published since then. 
Therefore we focused on data published in the 21th century, limiting the article search and 
selection to the period between 2000 and 2018. 
4.2. Search Strategy and Eligibility Criteria 
This research was conducted between February and March of 2018 in order to obtain the most 
recent literature. The last access took place on the 31th of March. 
Forthose articles which did not had free access or had incomplete data, the authors were 
contacted directly.  
Manual research consisted in access references lists of pubmed articles, articles 
recommended by the advisors, government reports on the INE and INSA platforms, and 
references from university libraries books. 
The eligibility criteria is: population-based cross-sectional or cohort studies studying people 
aged 15 or more years, conducted on or after 2000 with hypertension prevalence data.. No 
language restrictions were applied. 
The studies published did not provide specific data for Portugal, did not provide data in an 
eligible format for extraction, did not evaluated the adult population, did not present 
prevalence data, evaluated specific groups (e.g. university students), were not population-
based, used a non-probability sample, did not provide stratified data or were published prior 
to 2000 were excluded. 
Hypertension Prevalence in Portugal: Systematic Review and Meta-analysis of Population-based Studies 















4.3. Study Selection and Data Extraction 
The identification of the literature was conducted as described above.  
Two independent reviewers assessed the eligibility of the studies, conducted through double-
titration of abstracts and titles. In the first screening, the identified studies were excluded by 
title or abstract because met explicit exclusion criteria. In the second step, we assessed the 
remaining manuscripts by full-text reading. For studies that used the same sample, the one 
Records screened 
(n=55) 


































Studies included in qualitative synthesis 
(n=11) 










Figure 1 - Flowchart of records retrieved, screened and included 





Terms] OR "hypertension"[All 
Fields]) AND 
("epidemiology"[Subheading] 
OR "epidemiology"[All Fields] 
OR "prevalence"[All Fields] 
OR "prevalence"[MeSH 
Terms]))) AND 
("portugal"[MeSH Terms] OR 
"portugal"[All Fields]) 
Additional records identified 
through other sources 
(article’s references, 





Hypertension prevalence not 
reported (n=3) 
Not published in 21th century 
(n=1) 
Same sample (n=3) 
Sample recruitment (n=5) 
Non-probability sample (n=2) 
Non Stratify Data (n=2) 
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with the biggest sample size was considered and, whenever possible, those presenting more 
strata-specific information. Following the above methodology, 11 studies(59,60,62,65–72) 
were selected meeting the inclusion criteria (Figure 1). 
After selecting the articles, the variables were extracted and organized into a Microsoft 
Office ExcelTM spreadsheet based on the STROBE checklist, using items: 4, 5, 6A, 7-10 , 12c-e, 
13a, 14b, 16a, and 17. The primary outcome of this meta-analysis was hypertension 
prevalence. Whenever a study had additional relevant data in another document, this 
information was included. Whenever necessary and possible, missing data by strata was 
calculated. The hypertension definitions of the selected studies are of two types: 
 SBP ≥ 140 and/or DBP ≥ 90 and/or BP lowering medication (BPLM) 
 Self-reported hypertension 
When a study had data on both of hypertension collected by clinical and surveillance method, 
we considered the one that had data by strata; if both provided strata data the extracted 
information was the one collected by the clinical method. 
 
 
4.4. Assessment Study Quality and Risk of Bias 
The methodological quality of included studies, including selection bias, measurement bias 
and bias related to data analyses, was assessed according to the reporting meta-analysis of 
observational studies (MOOSE) checklist.(73)  
Selection bias was considered if ≥20% of the selected sample refused to participate in the 
study or if data collection was not made through an actual interview. Non-random sampling 
was not considered because all studies selected had probability samples. 
Measurement biases were defined considering the type of device used and measurement 
methods for BP recording (e.g. discard of the first measurement), except for self-reported 
hypertension. 
Bias related to data analyses was considered if the design effect was not accounted for the 
calculation of prevalence. 
After individual assessment for bias and methodological quality, all studies included in this 
systematic review presented fair or good internal validity. 
4.5. Data Analysis  
All estimates of the analyses and their 95% confidence intervals (95% CI) were calculated 
using the random effects model according to the decade of inclusion of participants, gender 
(when possible) and age groups. The choice was based on the possibility that the different 
studies had evaluated different populations, since most of the included studies evaluated only 
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local population bases. Such a hypothesis could explain the heterogeneity expected in the 
present meta-analysis. However, even considering the possibility of heterogeneity, the 
analysis by the fixed effects model was also evaluated, with no differences in the estimates, 
despite having narrower confidence intervals. 
Heterogeneity and consistency were assessed through Cochran's Q and I2 statistics, 
respectively. Analyses and forest plots were performed using the software Comprehensive 
Meta-AnalysisTM version 3 – free trial. 
Subgroups analysis was performed considering gender as well as age groups. Trends in 
hypertension prevalence were obtained through direct comparison of hypertension 
prevalence’s in the first and second decade of the 21st century, considering data collection 
date intervals. Sensitivity analyses of data were also carried out to test for small-sized study 
bias with no differences in the presented results. 
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In this section we present the findings of the systematic review and meta-analysis. Due to 
meta-analysis accuracy, whenever possible we will present the statistic findings.  
5.1. Synthesis of Data 
Based on the defined strategy (see page 9 -Materials and Method section), Pubmed search 
identified 22 articles; 33 additional records (4 reports, 1 thesis, 1 poster and 27 articles) were 
obtained from other sources (INE, INSA, advisors’ suggestions and article references).  
An initial screening, based on paper titles and abstracts, lead to the rejection 28 results; 27 
documents were fully accessed and checked for eligibility criteria. 
A total of 11 results(59,60,62,65–72) published between 2000 and March of 2018, were 
considered eligible to this study, 4 reports(62,70–72) (carry out by governmental institutions) 
and 7 articles(59,60,65–69) published in scientific journals. All results have data stratified by 
age and total prevalence (supplementary material, section 9). Three are studies from local 
communities, other 3 present data from Portugal mainland and the remaining 5 have data 
from all country. Five studies also present stratification by region. The recruitment followed 
various methods (2 used telephone lists, 4 primary healthcare centers (PHC) lists, 4 were 
based on location). Data was presented using variable strata definitions for age, gender and 
region. 
The total number of participants in these studies was 154585 individuals. The sample size 
varies between 340, in a local study(65), and 41573, in the 1998-1999 National Health 
Survey(70). People included were 15 or more years-old and female participation was between 
51.2% and 61.5%. The  2005-2006 National Health Survey sample(71) took into account the 
2001 Portuguese CENSUS; as a result the female/male rate was higher than 50%.   
The study designs were cross-sectional in 8 studies(59,60,62,65,66,70–72) and 3 were cohort 
studies(67–69). Data collection took place between 1998 and 2015. In all studies BP 
measurement was obtained cross-sectionally.  
5.2. Study Characteristics 
5.2.1. Sample Calculation 
In all the studies included, the authors calculated representative samples of the people they 
intended to study. 
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Local studies considered the people living in those places. National health surveys of 1998-
1999 and 2005-2006 took into account the people from CENSUS (1991 and 2001, respectively). 
CENSUS 2001 also served to estimate the sample of other 3 studies(59,60,66). 
Five studies(59,60,62,66,68) took also into account the expected or theorical prevalence (of 
hypertension or other measure) in the population. Multistage methodology was used in 6 
studies.(62,66,68,70–72) Cunha et al(67) took into account predictable nonadherence and 
dropout proportions. 
5.2.2. Recruitment 
The recruitment was different among the studies (see supplementary material, section 9). 
Address, telephone lists or PHC lists were used to recruit people. In Portugal not everyone 
have a family doctor or are enrolled in PHC(74) ,thus the studies that used PHC lists could not 
took into account every single person living in Portugal. Cunha et al, used PHC lists, but 
before recruiting they analysed the differences between local citizens’ registers and PHC lists 
and concluded that difference was not significant. Every study described the way they 
contact and invited people (personally, telephone or letter). Seven studies have 
nonadherence data, or it was possible to estimate its value. This rate varied between 0% and 
30%. It is important to notice that samples were probabilistic and the people invited was 
selected using a randomize methodology. 
5.2.3. Methodology of Recording BP 
BP data collection was obtained by interview, physical measurement or both. In the studies 
where BP was self-reported (SR), 4 were personal face-to-face interviews(66,70–72) and one 
use telephone interviews(68). Whenever BP was collected both ways, the clinical method was 
the preferred to extract data. This occurred in 2 studies that revealed higher hypertension 
prevalence rates using the later method.(59,67) In the 6 studies that recorded BP by physical 
measure (PM)(59,60,62,65,67,69), 4 used automatic devices and 2 standard mercury devices. 
Different number of measures and time of rest before and between the measures was also 
used (supplementary material, section 9); however 2 studies referred the use of international 
guidelines.(59,69)  The arm selection varied, but every study referred that the size of arm 
was taken into account when choosing the cuff. 
Only two studies performed BP measurements in more than one visit.(60,67) In both visits BP 
measurements used the same methodology, what is in accordance with international 
guidelines(75), therefore avoiding BP prevalence overestimates.  
In 4 of the 6 studies that have performed physical measurements, precautions were taken to 
not influence the BP results. Participants were advised not to drink caffeine and/or alcohol 
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beverages, not to drink tea, not to smoke, not to make exercise and fast for at least 30 min 
prior to the measurement in 3 of the studies and 8 hours in the other one (supplementary 
material, section 9). 
5.2.4.  Prevalence 
Hypertension prevalence data was collected and the methodology of each study to access this 
condition was taken into account. 
When the study measure is hypertension by the awareness of the participants about them 
health status, the SR measure defines hypertension. When a physical exam was performed the 
definition for those studies was the same: SBP ≥ 140 and/or DBP ≥ 90 and/or BPLM. 
All studies present total hypertension prevalence rates stratified by age. However, not all 
studies used the same stratification (supplementary material, section 9). Three of these 
studies considered shorter age groups (one between 25-44, another age equal or higher than 
40 years, and another one age equal or higher than 65 years of age). Ten studies present 
results by gender.  
For studies in which hypertension is exclusively SR, the prevalence is higher in women (Figure 
2). On the other hand, among those in which hypertension is measured through automatic or 
standard mercury devices the prevalence is higher in men (Figure 3) 
 
Figure 2 – Studies with SR Hypertension  
When we look to the prevalence among the studies with SR hypertension, prevalence 
estimates range between 19.9%(70) and 25.3%.(72) However, the most recent published study 
presents a prevalence of 57.3% but it included only individuals 65 or more years of age.(68) 
Among studies that recorded BP with PM, regional studies present values that range between 
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36.0% and 42.2%. Two of those provide a decade comparison (Table 3)
 
Figure 3 – Studies with PM 
without showing significant differences in total prevalence and in women (38.9% to 40.2%), 
but demonstrate a 5% decrease among men (49.5% to 44.4%). Simões et al(65) in a study 
conducted between 1998 and 1999, identified a prevalence of 20.3% in a city called Góis, in 
the central region of Portugal. Simultaneously, INE conducted a study in 1998-1999 that 
identifies a prevalence of 19.9% in Portugal mainland(70). In addition, INE conducted a 
National Heath Survey in 2014 that identified prevalence for Portugal of 25.3%.(72) However, 
INSA and INE conducted a National Health Survey with Physical Exam in 2015 and identified 
prevalence of 36.0% in Portugal.(62) Cunha et al(67) reports a hypertension prevalence, for 2 
cities in the north of Portugal, of 31.6%, what is less than the result obtained by Polónia et 
al(60) for Portugal mainland (42.2%), in the same period. 
Among the studies with data stratified by age groups, 4 studies(59,60,65,67) reveal an 
increasing prevalence as age increases in both genders. 
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Five studies have data from the 7 Portuguese regions (North, Centre, Lisbon, Alentejo, 
Algarve, Azores and Madeira). Figure 4 shows hypertension prevalence in the different regions 
by study. Nevertheless it should be emphasized that these studies use different age ranges 
and Algarve region have the lower hypertension prevalence in 3 of the 5 studies. 
 
5.3. Assessing Bias 
The studies selected were published in 2000 (2 results), and one in each of the following 
years - 2005, 2008, 2010, 2011, 2014, 2015, 2016 (2 results) and 2018. There is not a study 
per year or a systematic period between studies. Also, there are not studies with data from 
the same year of CENSUS 2001 and CENSUS 2011. 
As previously mentioned, sample size varies significantly, between 340 and 41537, with a 
median of 4910. Information about the methodology to calculate the sample size is explained 
in every study, as well the methodology of recruitment which is different among the studies 
and may have influenced the possibility of participation of the population (e.g., Polónia et 
al(60) just consider 84% of population because made the recruitment based in PHC lists). 
However, every sample is randomized, probabilistic and multistage cluster sampling. 
Non-participation rate is not described by every study, and among those who presented this 
value was inferior to 30%. Of the entire studies just one used a telephone interview. Among 
the studies with PM, 2 discarded the first measure and another study discard the firs measure 
if the difference between the 1st and 2nd measure was superior to 10mmHg. The number of 
measures was different as well as the time before and between measures, but the researches 
were very cautious in cuff selection. The different age-stratification place major difficulties 
to obtain comparable information. Only 4 studies control factors (like smoking or drink tea 
before PM) those could influence the BP results. 
As referred before (page 10, Materials and Methodologies section), whenever was possible we 
calculated data that was not available. 
 
5.4. Meta-Analyses Results 
5.4.1. Prevalence 
Overall hypertension prevalence (Figure 5), regardless of gender, age, settings, and BP 
measurement methods, was available in all studies (n=154585) varying from 19.9%16 to 57.3%. 
The summary measure - hypertension prevalence - was 33% (95% CI: 27.0% - 38.8%, I2: 45%). 
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Figure 5 – Overall hypertension prevalence in Portugal 
5.4.2. Gender-Specific Prevalence 
10 of the 11 studies included in the present thesis provided gender-specific data on 
hypertension prevalence in Portugal. However, only 8 studies provide data that allows 
gender-specific prevalence meta-analysis (supplementary material, section 9). 
Specific to women (n=34997), the pooled prevalence was 32.9% (95% CI: 27.1% - 38.4%) The 
pooled prevalence of hypertension in men (n=30025) was 35.4% (95% CI: 24.3% - 48.3%). 
Despite the difference in prevalence between men and women, it is not significant. 
5.4.3. Age-Specific Prevalence 
In 8 studies it was possible extract, or calculate, data by 3 stratum, <35, 35-64 and >65 
(supplementary material, section 9). 
Two of those are from local regions, Góis and Porto. The other ones are from continental 
Portugal (3 results) and Portugal as a whole (3 results). 
Population in age group 15-34 years (n=30487) have a hypertension prevalence of 7.1% (95% 
CI: 3.8% - 12.8%). The same studies were used to calculate the prevalence in age group 35-64 
(n=53720) that is 36.8% (CI: 35.2% - 38.4%). In the last age group, equal or above 65 years of 
age (n=24363), 8 studies were analyzed, but in this analyses Simões et al (2000) was excluded 
because people from this age group was not evaluated, and Canhão et al (2018) was included 
because the sample had 65 or more years of age. The hypertension prevalence estimate is 
65.3% (95% CI: 56.5% - 73.0%). Overall it is possible to identify an increasing of hypertension 
prevalence with an advancing in age of the population. 
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5.4.4. Comparison per Decade 
The comparison between decades is not statistically significant.  
However, when analysed by type of recording BP it is possible to identify a decreasing trend 
in both younger (<35) and older (≥65) age groups over the period, which is statistically 
significant for PM.(59,60,62,65,67,69) 
Table 4 - Hypertension Prevalence per Decade by age-group 
 
2000 - 2010 2011 - 2018 
<35 16.3% (95% CI: 12.9% - 20.5%) 6.3% (95% CI: 5.3% - 7.6%) 
35-64 41.1% (95% Ci: 34.2% - 48.4%) 41.7% (95% CI: 32.2% - 51.9%) 
≥65 80.4% (95% CI: 76.9% - 83.5%) 73.2% (95% CI: 69.5% - 76.6%) 
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The result of the summary measure – hypertension prevalence - calculated in the present 
thesis is 33.0% (95% CI: 27.6% - 38.8%, I2: 45%). As described before (see page 8 Materials and 
Methods section),we only included population-based studies with randomized and non-
specific population samples in order to have representative samples of the population 
considered in the articles assessed (regional, continental or national). 
Other important findings demonstrate that when hypertension is SR the prevalence is higher 
in women. In other hand, among those in which hypertension is measured by automatic or 
mercury standard devices the prevalence is higher in men (Figure 2 and 3). This may 
demonstrate that women have better awareness about their health than men, what is in 
accordance with studies about hypertension awareness.(59,60,69) 
In the studies with PM the summary measure was 37.1% (95% CI: 31.8% - 42.8%). This 
prevalence is higher than in studies with SR hypertension, 28.6% (95% CI: 23.6% - 34.3%). The 
huge difference in results among these 2 recording BP methods demonstrate that SR 
hypertension underestimate the prevalence of hypertension when compares to hypertension 
recorded with PM, which is also in accordance with other authors.(76) Scientific societies(13–
19) recommend that the physicians perform BP recording with PM in more than 1 visit or with 
out-of-office methodologies to determinate the BP. Thus, scientific studies must use PM 
methodology, with electronic device, and record BP in more than 1 visit or use an out-of-
office measure and, therefore allow hypertension prevalence estimates more 
accurate.(75,77) 
The meta-regression did not demonstrate a defined trend in hypertension prevalence over 
this century. However, when we analysed the studies with PM, stratified by age and gender, 
in two periods (2000-2010 and 2011-2018) we observe a statistically significant decrease in 
younger (<35) and older (≥65) age groups (Table 3).  
In a systematic review about hypertension prevalence between 1990 and 2005(58), Pereira et 
al demonstrate an increasing trend in all age-groups and both genders for SR hypertension 
between 1990 and 2005, and also evidenced a decreasing in hypertension prevalence in 
middle and older age-groups. In the present systematic review we observe an increasing SR 
hypertension (Figure 6) in age-group >65 although the meta-regression per decade for studies 
with PM show us a different trend (Table 3).  
In a pooled analysis of the Zhou B et al(51), including 1479 population based measurement 
studies with 19.1 million participants from all continents from 1975 to 2015, hypertension 
prevalence in 2015 was 24.1% in men and 20.1% in women, whereas in Portugal we identified 
35.4% (95% CI: 24.3% - 48.3%) in men and 32.9% (95% CI: 27,1% - 38,4%) in women; if we just 
consider studies with PM the hypertension prevalence is 43.0% (95% CI: 38.0% - 48.2%) in men 
and in 35.5% (95% CI: 29.1% - 42.4%) women, what is considerable higher than Zhou et al 
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demonstrate to the world. The analyses from Zhou B et al served to WHO estimate global, 
regional and country prevalence for the year 2015. WHO referred the prevalence worldwide 
in 2015 was 22.1% and estimates 24.4% hypertension prevalence for Portugal(63), what is well 
below the estimates obtained in this analysis.  
 
Figure 6 –Prevalence of SR hypertension by study and stratified by age-group 
Hypertension prevalence in Portugal is lower than in China (44.7%)(78) and Russia (52%)(79), 
but higher than in USA (29%)(57), Mexico (31.5%)(80), Brazil (31%)(52), African Continent 
(30.8%)(81), India (29.8%)(55), South-Asia countries (27.1%)(82) and Australia (21%)(83). 
For European Continent, WHO estimates a hypertension prevalence of 23.2% for 2015(63), 
which is 10 points inferior compare to our findings. In other hand, Tolonen H et al(84) 
described the recent results of European Health Examination Survey (EHES) and concluded 
that in Europe 33.1% of men and 22.8% of women are hypertensive. The results by gender of 
the present meta-analyses re similar in men 35.4% (95% CI: 24.3% - 48.3%), but 11 points 
higher in women, 32.9% (CI: 27.11% - 39.4%). 
A comparison with other European countries, we find lower prevalence’s of hypertension in 
Italy (25.1%)(85), Germany (31.8%)(86) and  England (28.3%)(87). In other hand, Spain 
(42.6%)(88), Serbia (42.7%)(89), Estonia (36%)(90) and Romania (40.4%)(91) have studies 
demonstrating higher prevalence’s.  
Nevertheless it should be emphasized that the use of different methodologies may play a 
crucial role in the prevalence estimates obtained. 
6.2. Strengths and Limitations 
The strengths of this review result from the importance of the risk factor analysed, the public 
health importance and consequences of the recent results published in Portugal, which 
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the quantitative analyses performed give us an accurate summary measure for Portugal, 
which was not described before in the scientific literature.  
Despite the number of studies for the summary measure being above the minimum 
recommendable to performed a meta-analysis(12), the number of studies across those 18 
years is low, not all took into account the different regions, and data age-stratification was 
variable. The differences in recruitment strategy, type of BP recording, and the number of 
visits observed in the different studies, as well the quality of the data calculated by the 
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The present analyses enable us to conclude the following: 
1) According to a meta-analysis of population-based studies, hypertension prevalence in 
Portugal on 21th is 33%; 
2) Hypertension prevalence increases with age; 
3) Hypertension prevalence among the elderly and in younger adults is lower in 2011-
2018 studies when compared to studies from the first 2000 decade; 
4) SR hypertension studies demonstrated a lower prevalence when compared to studies 
with PM, suggesting an under-estimation of hypertension by the SR method; 
5) Further studies are needed to conclude about hypertension trends in Portugal in the 
21st century; 
As described, hypertension is a prevalent health problem of 21th century in Portugal. 
Government policies, like salt-intake measures(92–94), are determinant to reverse this 
situation and improve Portuguese people health.  
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2542 55,1 ≥18 Guimarães/
Vizela 
PHC list Cohort Age, 
Gender 
<24 
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INSA, 2016 INSA, 
advisor 









2393 55,8 ≥65 Portugal Address Cohort Age, 
Region 
NA 
INE: Portuguese Statistics Institute; INSA: Portuguese Health Institute; NA – Not Available; PHC – 
Primary Healthcare Centres. 
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9.2. Annex 2 
Table 6 - Characteristics of Blood Pressure measurements 
First Author 






























NA PM SM NA 2/1 5/5 20.3 NA 
INE, 2000 NA SR NA NA NA NA 19.9 NA 
Macedo ME, 
2005 




INE,  2008 NA SR NA NA NA NA 23.4 NA 
Pereira M, 
2010 




















INE, 2016 NA SR NA NA NA NA 25.3 NA 
INSA, 2016 NA PM Auto R **3/1 5/1 36 NA 
Canhão H, 
2018 
NA SR NA NA NA NA 57.3 NA 
Auto – Automatic; BP – Blood Pressure; HTN – Hypertension; L – Left; NA – Not Available; PM – 
Physical Measure; R – Right; SM – Standard Mercury; SR – Self-Reported; 
a the arm with the highest first reading served for the next two measures; 
* If measure between 1st and 2nd had more than 10mmHg difference, just account the last 2 
measures 
** Just account the last 2 measures 
 
